Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS20049945HPVENSG00000173599.15protein_codingPCNoNo5091P11498
TVIS20049676HPVENSG00000173599.15protein_codingPCNoNo5091P11498
TVIS20021038HPVENSG00000173599.15protein_codingPCNoNo5091P11498
TVIS44004312HTLV-1ENSG00000173599.15protein_codingPCNoNo5091P11498
TVIS44046606HTLV-1ENSG00000173599.15protein_codingPCNoNo5091P11498
TCGA Plot Options
Drug Information
GenePC
DrugBank IDDB00119
Drug NamePyruvic acid
Target IDBE0000698
UniProt IDP11498
Regulation Type
PubMed IDs16505973; 16575559; 16740637; 16765071; 17008113
CitationsJitrapakdee S, Vidal-Puig A, Wallace JC: Anaplerotic roles of pyruvate carboxylase in mammalian tissues. Cell Mol Life Sci. 2006 Apr;63(7-8):843-54.@@Simpson NE, Khokhlova N, Oca-Cossio JA, Constantinidis I: Insights into the role of anaplerosis in insulin secretion: A 13C NMR study. Diabetologia. 2006 Jun;49(6):1338-48. Epub 2006 Mar 31.@@Jensen MV, Joseph JW, Ilkayeva O, Burgess S, Lu D, Ronnebaum SM, Odegaard M, Becker TC, Sherry AD, Newgard CB: Compensatory responses to pyruvate carboxylase suppression in islet beta-cells. Preservation of glucose-stimulated insulin secretion. J Biol Chem. 2006 Aug 4;281(31):22342-51. Epub 2006 Jun 1.@@Ikeda K, Yukihiro Hiraoka B, Iwai H, Matsumoto T, Mineki R, Taka H, Takamori K, Ogawa H, Yamakura F: Detection of 6-nitrotryptophan in proteins by Western blot analysis and its application for peroxynitrite-treated PC12 cells. Nitric Oxide. 2007 Feb;16(1):18-28. Epub 2006 May 4.@@Liu L, Li Y, Zhu Y, Du G, Chen J: Redistribution of carbon flux in Torulopsis glabrata by altering vitamin and calcium level. Metab Eng. 2007 Jan;9(1):21-9. Epub 2006 Aug 12.
GroupsApproved; Investigational; Nutraceutical
Direct ClassificationAlpha-keto acids and derivatives
SMILESCC(=O)C(O)=O
PathwaysCitrullinemia Type I; 4-Hydroxybutyric Aciduria/Succinic Semialdehyde Dehydrogenase Deficiency; Glycogenosis, Type IB; Argininemia; Pyruvate Kinase Deficiency; Pyruvate Carboxylase Deficiency; Amino Sugar Metabolism; The Oncogenic Action of Fumarate; 3-Phosphoglycerate Dehydrogenase Deficiency; Glycolysis; Non-Ketotic Hyperglycinemia; 2-Hydroxyglutric Aciduria (D and L Form); Glucose-Alanine Cycle; G(M2)-Gangliosidosis: Variant B, Tay-Sachs Disease; Alanine Metabolism; Hyperglycinemia, Non-Ketotic; Cystinosis, Ocular Nonnephropathic; Dimethylglycine Dehydrogenase Deficiency; Glycogenosis, Type VII. Tarui Disease; Dihydropyrimidine Dehydrogenase Deficiency (DHPD); Lactic Acidemia; Homocarnosinosis; Primary Hyperoxaluria Type I; Ornithine Transcarbamylase Deficiency (OTC Deficiency); The Oncogenic Action of L-2-Hydroxyglutarate in Hydroxygluaricaciduria; Sarcosinemia; Urea Cycle; Phosphoenolpyruvate Carboxykinase Deficiency 1 (PEPCK1); Cysteine Metabolism
PharmGKBPA164778686
ChEMBLCHEMBL1162144